Resectable Sinonasal Mucosal Melanoma in the Immunotherapy Era: Upfront Surgery vs. Neoadjuvant Therapy
Head & Neck · 2025
DOI: 10.1002/hed.28098 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Head & Neck, 2025. Verfasst von Aya F Salem und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Melanoma, Immunotherapy, Paranasal Sinus Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Radiological Society of North America, NCATS NIH HHS.
Abstract (Originalsprache)
Objective
We aim to evaluate outcomes for patients with resectable SNMM treated in the immunotherapy era.
Methods
Thirty‐seven patients with resectable SNM were identified using our institutional database between 2016 and 2023.
Results
Patients receiving neoadjuvant Ipi/Nivo (46%, n = 17) were more likely to have disease involving the sinuses and/or the skull base (71% vs. 35%, p = 0.05). The overall response rate to Ipi/Nivo was 24%. Two‐year LRFS from the start of therapy was 63%, and from the end of local therapy was 78%. Two‐year PFS was 49%. The patients who received Ipi/Nivo with evidence of response ( n = 4, 24%) had better PFS (2‐year PFS 100% vs. 15%, p = 0.02) and LRFS (2‐year LRFS 100% vs. 31%, p = 0.08).
Conclusions
Outcomes for resectable SNMM patients continue to be poor in the immunotherapy era. In the context of selection bias, neoadjuvant Ipi/Nivo was not associated with better outcomes in all‐comers. However, those with evidence of response to Ipi/Nivo had better prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Neuroradiology Department, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Aya F Salem, Shirley Y Su
Förderung
- NCI NIH HHS
- Radiological Society of North America
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
- National Cancer Institute
Zitieren
APA
Salem, A. F., Chen, M. M., Williams, M. D., Swanson, D. M., McQuade, J. L., Amaria, R. N., Hanna, E. Y., Bishop, A. J., Farooqi, A. S., Guadagnolo, B. A., Su, S. Y., & Mitra, D. (2025). Resectable Sinonasal Mucosal Melanoma in the Immunotherapy Era: Upfront Surgery vs. Neoadjuvant Therapy. Head & Neck. https://doi.org/10.1002/hed.28098
Vancouver
Salem AF, Chen MM, Williams MD, Swanson DM, McQuade JL, Amaria RN, et al. Resectable Sinonasal Mucosal Melanoma in the Immunotherapy Era: Upfront Surgery vs. Neoadjuvant Therapy. Head & Neck. 2025. doi:10.1002/hed.28098
BibTeX
@article{Salem2025,
author = {Salem, Aya F and Chen, Melissa M and Williams, Michelle D and Swanson, David M and McQuade, Jennifer L and Amaria, Rodabe N and Hanna, Ehab Y and Bishop, Andrew J and Farooqi, Ahsan S and Guadagnolo, B Ashleigh and Su, Shirley Y and Mitra, Devarati},
title = {Resectable Sinonasal Mucosal Melanoma in the Immunotherapy Era: Upfront Surgery vs. Neoadjuvant Therapy},
journal = {Head & Neck},
year = {2025},
doi = {10.1002/hed.28098}
}
EUVIMED